<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00420823</url>
  </required_header>
  <id_info>
    <org_study_id>MHREC 2006/040</org_study_id>
    <secondary_id>SMRI Grant ID Number 06T-811</secondary_id>
    <nct_id>NCT00420823</nct_id>
  </id_info>
  <brief_title>A Study of Taurine in Patients With First-episode Psychosis Receiving Antipsychotic Treatment</brief_title>
  <official_title>A 12-week, Parallel, Double-blind, Randomised, Placebo-controlled Adjunctive Study of Taurine 4 Grams in 128 Patients With First-episode Psychosis Receiving Antipsychotic Treatment.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Melbourne Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Stanley Medical Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Southern Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Melbourne Health</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether Taurine 4g is effective with antipsychotic&#xD;
      medication in the treatment of First Episode Psychosis.Taurine may have an effect on&#xD;
      cognition and symptoms. We are examining changes in symptoms and cognition over a 3 month&#xD;
      period.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The core rationale of this study will be to prospectively investigate whether Taurine will&#xD;
      improve and /or protect cognitive functioning and improve symptomatology in a cohort of 128&#xD;
      first episode psychosis patients.This is a randomized, double blind placebo controlled add on&#xD;
      standard therapy trial of Taurine 4g , in young patients between 18-25 presenting to ORYGEN&#xD;
      Youth Health a sub program of Melbourne Health and RAPPS, a subprogram of Southern Health&#xD;
      with a first psychotic episode . Taurine will be compared with placebo added to standard&#xD;
      treatment for a period of 12 weeks in a double blind fashion.Primary outcome measures will be&#xD;
      psychopathology and cognition (MATRICS.&#xD;
&#xD;
      Secondary outcome measures will be tolerability and safety measures (drop-out rates, general&#xD;
      side effect scale (UKU).&#xD;
&#xD;
      Patients who give informed consent will be randomised to receive treatment with Taurine 4g&#xD;
      daily or placebo for 12 weeks.&#xD;
&#xD;
      Patients will be randomised by a dynamic randomisation method called minimization which&#xD;
      allocates patients to treatment group by checking the allocation of similar patients already&#xD;
      randomised, and allocating the next treatment group &quot;live&quot; to best balance the treatment&#xD;
      groups across all stratification variables. The minimization will be carried out by the NHMRC&#xD;
      clinical trials centre in Sydney , and the patient will be randomized to either placebo or&#xD;
      vitamin.&#xD;
&#xD;
      Each patient will collect their tablets from the clinical trials pharmacy. The Clinical&#xD;
      Trials Pharmacy will dispense either vitamin or placebo. All study personnel and participants&#xD;
      will be blinded to treatment assignment for the duration of the study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2007</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cognition (MATRICS Composite score) at 3 months</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Symptomatology at 3 months</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety at 3 months</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerability at 3 months</measure>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">121</enrollment>
  <condition>Psychotic Disorders</condition>
  <arm_group>
    <arm_group_label>Placebo pill</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>4 placebo pills daily for 3 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Taurine 4g</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Taurine 4g daily comprising four 1g pills</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Taurine 4g</intervention_name>
    <arm_group_label>Placebo pill</arm_group_label>
    <arm_group_label>Taurine 4g</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male and females&#xD;
&#xD;
          -  Between 18 and 25 years of age&#xD;
&#xD;
          -  First Episode Psychosis&#xD;
&#xD;
          -  Attending ORYGEN Youth Health, a geographical based catchment area service for young&#xD;
             people aged between 15 and 25.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Organic disorders presenting with a psychotic syndrome (e.g. brain tumour, temporal&#xD;
             lobe epilepsy, HIV encephalopathy)&#xD;
&#xD;
          -  Mental retardation (unable and/or unlikely to give appropriate information of&#xD;
             symptomatology or side-effects (IQ approximately lower than 80)&#xD;
&#xD;
          -  History of clinically significant physical illness (e.g. terminal cancer, renal&#xD;
             dialysis)&#xD;
&#xD;
          -  History of brain surgery&#xD;
&#xD;
          -  History of brain infarction&#xD;
&#xD;
          -  Pregnant or lactating women or women of childbearing potential not using an acceptable&#xD;
             method of contraception.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>25 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr Colin P O'Donnell, MB,MRCPsych</last_name>
    <role>Principal Investigator</role>
    <affiliation>ORYGEN Research Centre , ORYGEN Youth Health,Department of Psychiatry,</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>ORYGEN Youth Health</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3052</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RAPPS programme, Southern Health</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <study_first_submitted>January 8, 2007</study_first_submitted>
  <study_first_submitted_qc>January 9, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 11, 2007</study_first_posted>
  <last_update_submitted>November 18, 2015</last_update_submitted>
  <last_update_submitted_qc>November 18, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 20, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>First Episode Psychosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psychotic Disorders</mesh_term>
    <mesh_term>Mental Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

